Zoetis Inc. $ZTS Shares Purchased by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 112,773 shares of the company’s stock after buying an additional 6,059 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Zoetis were worth $16,501,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new stake in Zoetis during the 1st quarter worth about $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC grew its holdings in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC raised its position in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of analyst reports. UBS Group decreased their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Barclays assumed coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday. KeyCorp started coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $160.18.

Zoetis Trading Down 0.3%

NYSE:ZTS opened at $122.34 on Friday. The business’s 50-day moving average is $128.86 and its two-hundred day moving average is $144.66. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The firm has a market capitalization of $53.91 billion, a PE ratio of 20.60, a price-to-earnings-growth ratio of 2.67 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio is 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.